Hajime Kato, MD, PhD
Associate Research Scientist in PathologyCards
About
Research
Publications
2024
Cardiovascular Outcomes of KCNJ5 mutated Aldosterone-Producing Adenoma: A Systematic Review.
Kato H, Kitamoto T, Kimura S, Sunouchi T, Hoshino Y, Hidaka N, Tsurutani Y, Ito N, Makita N, Nishikawa T, Nangaku M, Inoue K. Cardiovascular Outcomes of KCNJ5 mutated Aldosterone-Producing Adenoma: A Systematic Review. Endocr Pract 2024 PMID: 38657793, DOI: 10.1016/j.eprac.2024.04.007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia.
Ito N, Hidaka N, Kato H. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinol Metab (Seoul) 2024 PMID: 38467164, DOI: 10.3803/EnM.2023.1908.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsExtended curettage for tumour-induced osteomalacia in the bone.
Okajima K, Kobayashi H, Ito N, Kato H, Ishibashi Y, Zhang L, Tsuda Y, Tanaka S. Extended curettage for tumour-induced osteomalacia in the bone. Jpn J Clin Oncol 2024 PMID: 38266040, DOI: 10.1093/jjco/hyad180.Peer-Reviewed Original ResearchFGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis
Hidaka, N, Inoue, K, Kato, H. et al. FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis. JACC Adv. 2024 Jan, 3 (1) . https://doi.org/10.1016/j.jacadv.2023.100747Peer-Reviewed Original Research
2023
Cartilage tissues regulate systemic aging via ectonucleotide pyrophosphatase/phosphodiesterase 1 in mice.
Arima T, Sugimoto K, Taniwaki T, Maeda K, Shibata Y, Tateyama M, Karasugi T, Tokunaga T, Sueyoshi T, Hisanaga S, Masuda T, Uehara Y, Yugami M, Matsushita K, Yonemitsu R, Kawakami J, Yoshimura N, Tanimura S, Kato H, Ito N, Inoue K, Bando K, Nakamura T, Miyamoto T. Cartilage tissues regulate systemic aging via ectonucleotide pyrophosphatase/phosphodiesterase 1 in mice. J Biol Chem 2023, 105512. PMID: 38042486, DOI: 10.1016/j.jbc.2023.105512.Peer-Reviewed Original ResearchThe pathophysiology of hypophosphatemia.
Ito N, Hidaka N, Kato H. The pathophysiology of hypophosphatemia. Best Pract Res Clin Endocrinol Metab 2023, 101851. PMID: 38087658, DOI: 10.1016/j.beem.2023.101851.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia.
Hidaka N, Murata H, Tachikawa K, Osaki K, Sekiyama T, Kinoshita Y, Kato H, Hoshino Y, Kimura S, Sunouchi T, Watanabe S, Nangaku M, Makita N, Michigami T, Ito N. The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia. JBMR Plus 2023, 7: e10842. PMID: 38130758, DOI: 10.1002/jbm4.10842.Peer-Reviewed Original ResearchGenetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal Ligaments
Kato H, Braddock D, Ito N. Genetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal Ligaments. Current Osteoporosis Reports 2023, 21: 552-566. PMID: 37530996, PMCID: PMC10543536, DOI: 10.1007/s11914-023-00814-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiffuse idiopathic skeletal hyperostosisAutosomal recessive hypophosphatemic rickets type 2Idiopathic skeletal hyperostosisSkeletal hyperostosisOPLL patientsGenetic factorsPathogenic variantsFibroblast growth factor 23Growth factor 23Posterior longitudinal ligamentSpinal ligament ossificationRecent FindingsRecent studiesStrong genetic factorImportant new biomarkerDisease courseFactor 23Longitudinal ligamentClinical evaluationPlasma biomarkersClinical trialsLigament ossificationPlasma PPiCalcification disordersPatientsEctopic calcificationThe effect of burosumab on intact and C-terminal FGF23 measurements.
Ashrafzadeh-Kian SL, Ito N, Srivastava T, Garg U, Kato H, Algeciras-Schimnich A, Bornhorst JA. The effect of burosumab on intact and C-terminal FGF23 measurements. Clin Endocrinol (Oxf) 2023, 99: 152-157. PMID: 36263608, DOI: 10.1111/cen.14832.Peer-Reviewed Original ResearchFGF23-related hypophosphatemia in a patient with small cell lung cancer: a case report and literature review.
Kato H, Kimura S, Taguchi M, Sunouchi T, Hoshino Y, Hidaka N, Edvige Foligno N, Koga M, Manaka K, Tamiya H, Kawakami M, Kage H, Yasunaga Y, Nangaku M, Makita N, Ito N. FGF23-related hypophosphatemia in a patient with small cell lung cancer: a case report and literature review. Endocr J 2023 PMID: 37468265, DOI: 10.1507/endocrj.EJ23-0086.Peer-Reviewed Original Research